Clinical Trials
315 trialsSPiReL
Sunnybrook Health Sciences Centre
DREAMM 14
GlaxoSmithKline
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Telehealth
Wake Forest University Health Sciences
MagnetisMM-9
Pfizer
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
MK-1454-002
Merck Sharp & Dohme LLC
GuidePath
Novartis
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
ELARA
Novartis
E7080-G000-231
Merck Sharp & Dohme LLC
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
SELECT
Amgen
The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
FIGHT-210
Incyte Corporation
TRANSFORM
Celgene
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
KarMMa
Celgene
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Big Ten Cancer Research Consortium
Study of Cemiplimab in Adults With Cervical Cancer
Regeneron Pharmaceuticals
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Dizal Pharmaceuticals
ALPINE
BeiGene
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
Eastern Cooperative Oncology Group
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Aprea Therapeutics
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aprea Therapeutics
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
MacroGenics
PRIMO
SecuraBio
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Pfizer
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Duke University
RATIONALE-309
BeiGene
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
TRANSCENDWORLD
Celgene
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
CAPITAL
AstraZeneca
CheckMate 914
Bristol-Myers Squibb